[HTML][HTML] Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non …
W Ma, Z Sheng, Y Niu, B Yan, Y Chen, H Yang, R Li - Heliyon, 2023 - cell.com
Introduction Although third-generation epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell …
W Ma, Z Sheng, Y Niu, B Yan, Y Chen, H Yang, R Li - Heliyon, 2023 - europepmc.org
Methods A retrospective analysis was conducted on a cohort of patients with EGFR-mutated
stage IIIA NSCLC who received treatment with either first-generation EGFR-TKIs or …
stage IIIA NSCLC who received treatment with either first-generation EGFR-TKIs or …
[HTML][HTML] Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non …
W Ma, Z Sheng, Y Niu, B Yan, Y Chen, H Yang, R Li - Heliyon, 2023 - ncbi.nlm.nih.gov
Methods A retrospective analysis was conducted on a cohort of patients with EGFR-mutated
stage IIIA NSCLC who received treatment with either first-generation EGFR-TKIs or …
stage IIIA NSCLC who received treatment with either first-generation EGFR-TKIs or …
[PDF][PDF] Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small …
W Ma, Z Sheng, Y Niu, B Yan, Y Chen, H Yang, R Li - researchgate.net
Introduction: Although third-generation epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell …
W Ma, Z Sheng, Y Niu, B Yan, Y Chen, H Yang… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Although third-generation epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell …
W Ma, Z Sheng, Y Niu, B Yan, Y Chen, H Yang… - Heliyon, 2023 - ui.adsabs.harvard.edu
Introduction. Although third-generation epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
[HTML][HTML] Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non …
W Ma, Z Sheng, Y Niu, B Yan, Y Chen, H Yang, R Li - Heliyon, 2023 - Elsevier
Introduction Although third-generation epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected …
Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell …
W Ma, Z Sheng, Y Niu, B Yan, Y Chen, H Yang, R Li - Heliyon, 2023 - europepmc.org
Methods A retrospective analysis was conducted on a cohort of patients with EGFR-mutated
stage IIIA NSCLC who received treatment with either first-generation EGFR-TKIs or …
stage IIIA NSCLC who received treatment with either first-generation EGFR-TKIs or …